Moderna recently announced that a second primary analysis of its COVID-19 vaccine candidate, mRNA-1273, found a 94.1 percent vaccine efficiency against the coronavirus.
The Phase 3 study, COVE,...
FDA recently issued an emergency use authorization to Regeneron for its COVID-19 antibody cocktail, formerly known as REGN-COV2.
The cocktail is made up of casirivimab and imdevimab.
The...
Johnson & Johnson recently initiated a second global Phase 3 clinical trial of its lead COVID-19 vaccine candidate, Ad26.COV2.S.
The trial, ENSEMBLE 2, is a pivotal, large-scale, Phase 3 trial...
Pfizer and BioNTech recently announced that they concluded their Phase 3 clinical trial after their mRNA-based COVID-19 vaccine candidate, BNT162b2, met all of the study’s primary efficacy...
FDA recently issued final guidance to encourage clinical trial diversity from the design to execution of the tests.
The guidance, Enhancing the Diversity of Clinical Trial...
GSK and biopharmaceutical company Medicago recently announced the start of Phase 2/3 clinical trials of its adjuvanted COVID-19 vaccine candidate.
The Coronavirus-Like Particle COVID-19 Vaccine...
Moderna recently announced that its mRNA COVID-19 vaccine candidate proved 95 percent effective in a Phase 3 clinical trial.
The candidate, mRNA-1273, met statistical criteria pre-specified in...
Humanigen and the Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense recently entered into a Cooperative Research and Development...
Merck recently signed a $2.75 billion pharmaceutical acquisition deal to purchase all outstanding shares of VelosBio, subject to certain customary adjustments.
Clinical-stage biopharmaceutical...
Pfizer and BioNTech recently announced that their mRNA-based COVID-19 vaccine candidate, BNT162b2, demonstrated evidence of efficacy against coronavirus in participants without prior evidence of...
Novartis and Molecular Partners AG recently announced a collaboration in the form of an option and license agreement to develop, manufacture, and commercialize Molecular Partners’ anti-COVID-19...
AstraZeneca recently announced that the Phase 3 clinical trial for its COVID-19 vaccine, AZD122, has resumed in the US after FDA deemed it safe to do so.
All clinical trials for AZD122 have now...
Johnson & Johnson recently announced that it will resume recruitment in the Phase 3 ENSEMBLE trial of its COVID-19 vaccine, Ad26.COV2-S, after the independent Data Safety and Monitoring Board...
FDA recently approved Verklury as the first COVID-19 treatment. The approval signs off on using the drug also known as remdesivir has been signed in adults and pediatric patients 12 years of age or...
CRISPR Therapeutics, recently announced positive top-line results from its ongoing Phase 1 clinical trial evaluating the safety and efficacy of its allogeneic CAR-T cell therapy that targets...
Sanofi and Translate Bio recently announced positive preclinical results for their mRNA-based COVID-19 vaccine candidate in mice.
Specifically, the candidate called MRT5500 induced "potent"...
Roche recently announced that it will launch a new high-volume COVID-19 antigen test, which will be made available at the end of 2020 for markets accepting the CE Mark.
The Elecsys SARS-CoV-2 Antigen...
AstraZeneca recently announced that its long-acting COVID-19 antibody combination will advance into two Phase 3 clinical trials at sites in and outside the US.
The first trial will evaluate the safety...
Bristol Myers Squibb recently announced results from a pivotal, placebo-controlled Phase 3 clinical trial evaluating its MS drug, Zeposia (ozanimod), in patients with ulcerative colitis...
Eli Lilly and Company and the Bill & Melinda Gates Foundation recently entered into an agreement to facilitate access to future COVID-19 antibody therapies in low-and middle-income...
